Discovery medicine · 2025
Improved Sampling Method to Enhance the Positive Rate of HER2 Detection in Gastric Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shi Huan, Liu Li-Qing, Qin Yue-Hong, Song Xi-Lin, Wen Xiao-Wen, Wang Long-Gang, Liu Bing, Sun Xu, Chai Jie, Wang Shi-Jiang, Liu Kai
Аннотация
BACKGROUND: To analyze the efficacy of the improved sampling method in enhancing the accuracy of Human Epidermal Growth Factor Receptor 2 (HER2) detection within gastric cancer surgical specimens, in order to decrease the false negative rate of HER2 detection results.
METHODS: In this study, the participants were gastric cancer patients recruited from the Shandong Cancer Hospital Affiliated with Shandong First Medical University. Between December 2018 to August 2020, 310 surgical specimens of gastric cancer were procured and processed using traditional sampling methods. Biopsy specimens (n = 235), and surgical specimens (n = 400) indicated for processing by improved sampling methods, were obtained during the period from September 2020 to July 2021. Clinical data including sex, age, stage, degree of differentiation, tumor site, operation duration and blood loss was collected. Sex, operation duration and blood loss among three groups were compared by One-Way analysis of variance (ANOVA), and sex, stage, degree of differentiation and tumor site comparisons were performed by Chi-squared test (χ2). HER2 detection was carried out for all specimens by means of immunohistochemical (IHC) assay. The results of HER2 detection among three groups were compared by Chi-squared test (χ2) using SPSS software.
RESULTS: There was no significant correlation between HER2 expression and pathological stage (p = 0.468). HER2 expression was related to tumor differentiation and tumor site: the HER2 expression in moderately differentiated tumors was higher than that in poorly differentiated tumors (p < 0.001); and it was significantly higher in gastric fundus than that in the gastric body and antrum (p = 0.031). The positive expression of HER2 in gastric cancer was 59.3% (0), 20.0% (1+), 13.4% (2+) and 7.3% (3+). Among them, a 2+ HER2 expression rate of 11.3%, 11.1%, and 16.5% were detected in specimens processed by the traditional sampling method, biopsy method, and tissues processed by improved sampling method, respectively. Meanwhile, a 3+ HER2 expression rate was found to be 4.8%, 8.1%, and 8.8%, respectively, for the specimens in the same order. Evidently, 1+ HER2 expression rate in specimens obtained by the improved sampling method and biopsy method was higher than in those by traditional sampling method (p < 0.001 and p = 0.007, respectively).
CONCLUSIONS: The improved sampling method significantly improves the positive HER2 expression rate (1+) in gastric cancer specimens, thereby reducing false-negative HER2 detection rates by immunohistochemistry. This method warrants further clinical implementation, particularly in resource-limited settings.
METHODS: In this study, the participants were gastric cancer patients recruited from the Shandong Cancer Hospital Affiliated with Shandong First Medical University. Between December 2018 to August 2020, 310 surgical specimens of gastric cancer were procured and processed using traditional sampling methods. Biopsy specimens (n = 235), and surgical specimens (n = 400) indicated for processing by improved sampling methods, were obtained during the period from September 2020 to July 2021. Clinical data including sex, age, stage, degree of differentiation, tumor site, operation duration and blood loss was collected. Sex, operation duration and blood loss among three groups were compared by One-Way analysis of variance (ANOVA), and sex, stage, degree of differentiation and tumor site comparisons were performed by Chi-squared test (χ2). HER2 detection was carried out for all specimens by means of immunohistochemical (IHC) assay. The results of HER2 detection among three groups were compared by Chi-squared test (χ2) using SPSS software.
RESULTS: There was no significant correlation between HER2 expression and pathological stage (p = 0.468). HER2 expression was related to tumor differentiation and tumor site: the HER2 expression in moderately differentiated tumors was higher than that in poorly differentiated tumors (p < 0.001); and it was significantly higher in gastric fundus than that in the gastric body and antrum (p = 0.031). The positive expression of HER2 in gastric cancer was 59.3% (0), 20.0% (1+), 13.4% (2+) and 7.3% (3+). Among them, a 2+ HER2 expression rate of 11.3%, 11.1%, and 16.5% were detected in specimens processed by the traditional sampling method, biopsy method, and tissues processed by improved sampling method, respectively. Meanwhile, a 3+ HER2 expression rate was found to be 4.8%, 8.1%, and 8.8%, respectively, for the specimens in the same order. Evidently, 1+ HER2 expression rate in specimens obtained by the improved sampling method and biopsy method was higher than in those by traditional sampling method (p < 0.001 and p = 0.007, respectively).
CONCLUSIONS: The improved sampling method significantly improves the positive HER2 expression rate (1+) in gastric cancer specimens, thereby reducing false-negative HER2 detection rates by immunohistochemistry. This method warrants further clinical implementation, particularly in resource-limited settings.